Share on StockTwits

InterMune (NASDAQ:ITMN) CEO Daniel G. Welch unloaded 3,914 shares of InterMune stock on the open market in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $39.19, for a total value of $153,389.66. Following the sale, the chief executive officer now directly owns 94,202 shares of the company’s stock, valued at approximately $3,691,776. The transaction was disclosed in a filing with the SEC, which is available at this link.

ITMN has been the subject of a number of recent research reports. Analysts at William Blair raised their price target on shares of InterMune from $41.00 to $48.00 in a research note on Thursday, May 22nd. Separately, analysts at ING Group upgraded shares of InterMune from a “market perform” rating to a “buy” rating in a research note on Monday, May 19th. They now have a $41.00 price target on the stock. Finally, analysts at Leerink Swann upgraded shares of InterMune from a “market perform” rating to an “outperform” rating in a research note on Monday, May 19th. They now have a $41.00 price target on the stock. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $39.08.

Shares of InterMune (NASDAQ:ITMN) traded up 2.28% during mid-day trading on Thursday, hitting $40.87. 1,774,305 shares of the company’s stock traded hands. InterMune has a 1-year low of $9.32 and a 1-year high of $41.24. The stock’s 50-day moving average is $35.49 and its 200-day moving average is $24.37. The company’s market cap is $4.041 billion.

InterMune (NASDAQ:ITMN) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.03. The company had revenue of $30.30 million for the quarter, compared to the consensus estimate of $28.24 million. During the same quarter in the previous year, the company posted ($0.64) earnings per share. The company’s revenue for the quarter was up 188.6% on a year-over-year basis. Analysts expect that InterMune will post $-2.34 EPS for the current fiscal year.

InterMune, Inc (NASDAQ:ITMN), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.